D-0120 not checked

InventisBio Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
4 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.”In the company’s words, NCT05504083 on ClinicalTrials.gov
Tested for
Hyperuricemia, Gout, Hyperuricemia or Gout
Main trialPhase 2
“This is a randomized, open-label, parallel-controlled, multicenter clinical trial in primary hyperuricemia patients with or without gout.”In the company’s words, NCT05504083 on ClinicalTrials.gov

Other drugs for Hyperuricemia

All 11 drugs for Hyperuricemia

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2Completed 18 May 2024 Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients
Phase 2Completed 31 Jul 2025 Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
Phase 1/2Completed 31 Dec 2021 D-0120 Safety and PK/PD Study in China
Phase 1Completed 30 Mar 2020 Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow D-0120

Following is part of Solo: you see every change to D-0120 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in